You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Current Perspectives in the Diagnosis and Treatment of Acute Intermittent Porphyria

  • Authors: Herbert L. Bonkovsky, MD; Angelika L. Erwin, MD, PhD; Brendan M. McGuire, MD, MS
  • CME / ABIM MOC / CE Released: 6/4/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/4/2021, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for gastroenterologists, emergency medicine physicians, pediatricians, PCPs, nurses, NPs, PAs, and other healthcare providers involved in the diagnosis and management of acute intermittent porphyria (AIP).

The goal of this activity is to discuss challenging patient cases to illustrate diagnosis, and acute and long-term management of patients with AIP.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Recognition of clinical presentations of AIP 
    • Diagnosis of AIP
    • Management of patients with AIP


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Herbert L. Bonkovsky, MD

    Professor of Internal Medicine and Gastroenterology
    Director, Liver Services
    Liver & Metabolic Disorders Laboratory
    Wake Forest Baptist Health Medical Center
    Winston-Salem, North Carolina

    Disclosures

    Disclosure: Herbert Bonkvosky, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alnylam Pharma; Mitsubishi-Tanabe, North America; Recordati Rare Chemicals
    Received grants for clinical research from: Alnylam Pharma; Gilead Sciences; Mitsubishi-Tanabe, North America

Panelists

  • Angelika L. Erwin, MD, PhD

    Assistant Professor of Genetics and Pediatrics
    Lerner College of Medicine
    Clinical Geneticist, Cleveland Clinic
    Cleveland, Ohio

    Disclosures

    Disclosure: Angelika L. Erwin, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alnylam Pharmaceuticals
    Served as a speaker or a member of a speakers bureau for: Sanofi Genzyme

  • Brendan M. McGuire, MD, MS

    Professor, Department of Gastroenterology and Hepatology
    Medical Director of Liver Transplant
    The University of Alabama at Birmingham
    Birmingham, Alabama

    Disclosures

    Disclosure: Brendan M. McGuire, MD, MS, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Arrowhead; Gilead; Mallinckrodt; Mitsubishi-Tanabe; Ocera

Editor

  • Pakinam Aboulsaoud, PharmD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse Planner

  • Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alnylam Pharmaceuticals
Received grants for clinical research from: Alnylam Pharmaceuticals


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Current Perspectives in the Diagnosis and Treatment of Acute Intermittent Porphyria

Authors: Herbert L. Bonkovsky, MD; Angelika L. Erwin, MD, PhD; Brendan M. McGuire, MD, MSFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 6/4/2020

Valid for credit through: 6/4/2021, 11:59 PM EST

processing....

Educational Impact Challenge

 
 
 
 

The goal of this activity is to discuss challenging patient cases to illustrate diagnosis, and acute and long-term management of patients with acute intermittent porphyria.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print